Table 3. Descriptive statistics on neutralizing antibodies against Ad5, Ad26, Ad35 and Ad48.
Median neutralizing antibody titers and interquartile ranges (IQR) as well as percentages of subjects with titers above the level of quantification (>18) for each population are shown. Geometric mean titers (GMT) and ranges are calculated among those subjects with quantifiable titers >18.
| SA infants | SA children | SA adults-1 high-risk |
SA adults-2 high-risk |
SA adults-3 high-risk |
Africa low-risk |
Kenya high-risk |
Uganda low-risk |
Thailand high-risk |
US low-risk |
US high-risk |
N/S America high-risk |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ad5, n | ND | 185 | 477 | 171 | 903 | 199 | 263 | 242 | 438 | 192 | 727 | 405 |
| Median, IQR | 493 (18-2528) | 410 (102-1169) | 391 (94-1069) | 366 (75-1106) | 506 (73-1726) | 877 (259-2369) | 505 (77-1501) | 521 (88-1328) | 18 (18-346) | 18 (18-388) | 25 (18-723) | |
| Positive (>18), n (%) | 122 (65.9) | 423 (88.7) | 153 (89.5) | 794 (87.9) | 166 (83.4) | 238 (90.5) | 209 (86.4) | 360 (82.2) | 74 (38.5) | 276 (38.0) | 210 (51.9) | |
| GMT (range) amongst positives | 1457 (21-16384) | 509 (19-16384) | 461 (20-16384) | 458 (19-16384) | 620 (20-16384) | 967 (19-16384) | 598 (19-16386) | 669 (20-16384) | 643 (20-16384) | 537 (19-16384) | 636 (19-16384) | |
| Ad26, n | 149 | 185 | 477 | 171 | 903 | 199 | 263 | 242 | 438 | 222 | 727 | 405 |
| Median, IQR | 18 (18-18) | 18 (18-21) | 20 (18-55) | 22 (18-65) | 18 (18-49) | 18 (18-40) | 37 (18-115) | 38 (18-132) | 30 (18-134) | 18 (18-18) | 18 (18-18) | 18 (18-19) |
| Positive (>18), n (%) | 1 (0.7) | 49 (26.5) | 244 (51.2) | 91 (53.2) | 389 (43.1) | 85 (42.7) | 174 (66.2) | 164 (67.8) | 239 (54.6) | 19 (8.6) | 110 (15.1) | 103 (25.4) |
| GMT (range) amongst positives | 32 (32-32) | 96 (19-1044) | 63 (19-1709) | 67 (19-682) | 69 (19-16384) | 61 (19-851) | 97 (19-4241) | 86 (19-1568) | 127 (19-3691) | 134 (21-768) | 94 (20-1190) | 85 (19-5527) |
| Ad35, n | 149 | 180 | 477 | 171 | 903 | 199 | 263 | 242 | 438 | 192 | 727 | 401 |
| Median, IQR | 18 (18-18) | 18 (18-18) | 18 (18-18) | 18 (18-18) | 18 (18-18) | 18 (18-18) | 18 (18-18) | 18 (18-18) | 18 (18-18) | 18 (18-18) | 18 (18-18) | 18 (18-18) |
| Positive (>18), n (%) | 0 (0) | 26 (14.4) | 85 (17.8) | 22 (12.9) | 96 (10.6) | 43 (21.6) | 39 (14.8) | 13 (5.4) | 75 (17.1) | 11 (5.7) | 55 (7.6) | 31 (7.7) |
| GMT (range) amongst positives | - | 51 (19-512) | 109 (19-16384) | 75 (21-783) | 111 (19-5440) | 55 (20-790) | 103 (26-315) | 50 (20-579) | 86 (19-4308) | 40 (19-78) | 166 (21-4798) | 76 (19-1099) |
| Ad48, n | ND | 178 | 477 | 171 | 903 | 199 | 263 | 242 | 438 | 192 | 726 | 405 |
| Median, IQR | 18 (18-18) | 18 (18-18) | 18 (18-18) | 18 (18-18) | 18 (18-18) | 19 (18-75) | 19 (18-69) | 18 (118-18) | 18 (18-18) | 18 (18-18) | 18 (18-18) | |
| Positive (>18), n (%) | 12 (6.7) | 115 (24.1) | 42 (24.6) | 120 (13.3) | 15 (7.5) | 134 (51.0) | 121 (50.0) | 56 (12.8) | 5 (2.6) | 89 (12.3) | 63 (15.6) | |
| GMT (range) amongst positives | 62 (22-455) | 49 (19-16384) | 38 (19-647) | 47 (19-1484) | 75 (22-3506) | 90 (19-9116) | 87 (19-16384) | 54 (19-3940) | 47 (26-116) | 86 (19-11279) | 67 (20-16384) |